Loading...
Market
How much additional funding will GSK commit to the Flagship Pioneering collaboration by December 31, 2025?
2
Resolution / Starting Odds
Up to $150 million • 25%
Up to $300 million • 25%
Up to $500 million • 25%
Up to $720 million • 25%
Official financial statements or press releases from GSK
Story
Flagship Pioneering and GSK Announce Multibillion-Dollar Collaboration to Develop 10 New Drugs and Vaccines
Jul 29, 2024, 11:12 AM
Flagship Pioneering and GSK have announced a strategic collaboration to discover and develop a portfolio of novel medicines and vaccines, focusing initially on respiratory and immunology. The partnership involves a multibillion-dollar deal to develop up to 10 new drugs. GSK has committed an initial investment of $150 million, with potential additional funding of up to $720 million in upfront, development, and sales milestones, along with tiered royalties for each acquired program. This collaboration aims to leverage GSK’s disease expertise and Flagship’s innovative approaches, including the use of generative artificial intelligence (AI) and high throughput chemical protein synthesis.
View original story
Similar markets
No additional funding • 25%
Up to $10 million • 25%
$10 million to $50 million • 25%
Over $50 million • 25%
Less than $100 million • 25%
$100 million to $200 million • 25%
$200 million to $300 million • 25%
More than $300 million • 25%
1-2 projects • 25%
3-4 projects • 25%
5-6 projects • 25%
More than 6 projects • 25%
Less than €100 million • 33%
Between €100 million and €500 million • 33%
More than €500 million • 33%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%
Less than €10M • 25%
Between €10M and €20M • 25%
Between €20M and €30M • 25%
More than €30M • 25%
Wave Life Sciences • 25%
ProQR Therapeutics • 25%
Korro Bio • 25%
Other • 25%